Member Info for CHELSEA7

From Vulpes and presume that lowers Calculas holding.

Well CH has been saying all aling ""All avenues are being considered"w and his last mail last week said a deriant ""We will keep the wheels going"" Never doubted him.

Again love Vulpes statement about long term.

And So Say All Of UsToday 07:44
Martin Diggle, Co-Founder and Portfolio Manager, Vulpes Investment Management, said:

"I am very pleased to be investing in Scancell at this exciting time in the company's evolution. Vulpes has been conducting scientific and commercial due diligence on Scancell for a considerable period of time. We have concluded the company's unique and innovative approach to fighting cancer is compelling and under-appreciated. At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly."

Note ""Long Term"

Came in at 6p and the share took off to 64p

Vulpes in at 5p and we take off to ??

Meant to say, well done all who saw us back to the 5s

So plus 5.61%.

Well done all

So plus 5.61%.

Well done all

5.30/6

Well done "1" code, lol.

Lags behind again!!!

Well TF I woke up at 6.30, then fell asleep again!!!

Can"t see how we were ever going to raise that amount in an OO, and we have on board a Fund who seriously believes in us. A very good ""interim situation" indeed, most importantly we will have two sets of data ready for whatever eventuality is next. Level 2 seems to like it too/

Martin Diggle, Co-Founder and Portfolio Manager, Vulpes Investment Management, said:



"I am very pleased to be investing in Scancell at this exciting time in the company's evolution. Vulpes has been conducting scientific and commercial due diligence on Scancell for a considerable period of time. We have concluded the company's unique and innovative approach to fighting cancer is compelling and under-appreciated. At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly."

Importantly...............................

Dr John Chiplin, Chairman of Scancell, said:



"We warmly welcome Vulpes as a shareholder and look forward to working with Martin Diggle. His extensive experience of investment management in the life science sector will add a valuable perspective and insight to the Board of Directors. This new investment capital increases funds available to advance our product pipeline and in particular, the transition of our lead Moditope® platform asset Modi-1 into the clinic."

And that allows us to gain early data in both SCIB1 and MOD1 trials,.............................

https://privatefunddata.com/private-funds/vulpes-life-sciences-fund/

Well, as has been said better than sub 2p, damn fell sleep again, who are Vulpes?

https://www.fiercebiotech.com/biotech/bio-ceos-weigh-biotech-companies-going-public-earlier-and-earlier?mkt_tok=eyJpIjoiWlRaaVpqSTJORGMwTm1ZNSIsInQiOiJsTGZaZ0JwbkNNUm1XY0d6czY0RWlLb2lISXBSVjNlSEliZnNzbUdVTkltRlc0NkdWQUk5WDNLbHF0TUIrTU1pSXI2dUFtS1NNZEpRaEtPd0dwMlU4bjlMRFwvUlwvSGVIR3FmWjB1b3lqMkVjS1BZZUtCckpFVE92WU5vXC9RMndOUCJ9&mrkid=36433381

Perhaps Scancell would/should give us an update in the SCIB1 U.S.A arm of the trial. We have been told it is Ichor who have to sort the issue out, they are an American company, so I don"t believe taking into account ""America First"" is the problem here. Makes you think though.

Fifteen days of grey sky and rain heralds in an ""summer day"" here in London, that"s probably Americas fault as well, lol.

Lets see what today brings us, 12 days to "first patient injected", time as ever flies by.

Soon find out Chester, wouldn"t take it too seriosly asindeed you are not. Still reading posts over there which I have been havingbproblems relating to the share.

More important what goe on here really,and news is something weexpect. aGoodnight All.

Of all the codes the one I have no faith in this the 1 code seen on shares where news is epected every couple of days.

They should always be careful what they wish for, IMHO

"""I think the plaudits and accolades are well deserved.
As for "no consequences" try telling the patients who are still alive that!"""

Very true Ruck. I just wonder how many/if any patients know what has kept them alive? I mentioned my best pal (he holds 300k shares here, my fault, lol) diagnosed with bladder cancer back then, had chemotherapy, surgery, which replaced his bladder for a plastic one, and immunotherapy before and a year after too, but doesn"t know what treatment he was given. Of small consequence really, he still does loads for me, but just gets tired very easily.

Wasn"t questioning your earlier post, just feel a disproportionate amount of trials are lung cancer and melanoma, hence increasingly better data, but none seems to get near Keytruda, and very little new data came out from Asco too, as far as I know.

So thats 2m volume this week, was hoping for more, but holding our SP well before the next news, which cannot be too long now. Good posts too Crumbs, not so easy to get that all down into a couple of posts, but you have and I haven"t really got anything much to add. Till tomorrow guys....................

370k Clearly Buys

2 x 100k Trades at 12.01...............possibly Bed & Isa

Leaving 550k probably sells

Very small range 5.24-5.445